Martina Taglieri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Martina Taglieri has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Poggi
Molecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy
1 shared publication - Chiara Rosa Maria Uras
Molecular Oncology and Angiogenesis Unit, Azienda Ospedaliera Metropolitana Liguria AOM-IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy
1 shared publication - Linda Di Gregorio
Molecular Oncology and Angiogenesis Unit, Azienda Ospedaliera Metropolitana Liguria AOM-IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy
1 shared publication
Latest Publications
- Open Access
- 9 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1302
NKR-P1A/CD161: A Multifunctional Immune Receptor at the Crossroads of Antitumor Immunity
The immune response of our body, whether it is directed to infective agents, allergens, or tumors, should support our recovery but can also be dangerous if dysregulated. There are molecular systems that have the role of tuning the immune response, such as activating and inhibitory receptors and co-stimulatory molecules. Among this plethora of receptors, immune-checkpoint receptors (ICRs), as well as natural killer receptors (NKRs), expressed on NK and/or T cells can up- or downregulate the function of activating and inhibitory receptors during immune cell crosstalk. Among NKRs, NKRP1A/CD161 has shown to be a promising target molecule for immunotherapy. This receptor showed inhibiting or co-stimulatory effects depending on the cell type analyzed as well as the analytical procedures, reagents used, and the experimental context. The aim of the following review will be to explore the structural and functional features of this receptor on immune cells, its relevance in the tumor microenvironment and its targeting as an immunotherapeutic tool in cancers.
- 9 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1302
Open AccessNKR-P1A/CD161: A Multifunctional Immune Receptor at the Crossroads of Antitumor Immunity
The immune response of our body, whether it is directed to infective agents, allergens, or tumors, should support our recovery but can also be dangerous if dysregulated. There are molecular systems that have the role of tuning the immune response, such as activating and inhibitory receptors and co-stimulatory molecules. Among this plethora of receptors, immune-checkpoint receptors (ICRs), as well as natural killer receptors (NKRs), expressed on NK and/or T cells can up- or downregulate the function of activating and inhibitory receptors during immune cell crosstalk. Among NKRs, NKRP1A/CD161 has shown to be a promising target molecule for immunotherapy. This receptor showed inhibiting or co-stimulatory effects depending on the cell type analyzed as well as the analytical procedures, reagents used, and the experimental context. The aim of the following review will be to explore the structural and functional features of this receptor on immune cells, its relevance in the tumor microenvironment and its targeting as an immunotherapeutic tool in cancers.